CompanyCyclo Therapeutics, Inc.
United States of America
Cyclo Therapeutics is a family of companies that provide Trappsol brand cyclodextrins and Aquaplex brand cyclodextrin complexes to researchers, R&D labs and industrial users in the medical, pharmaceutical, food, and nutritional industries.
Private/Public:
public
Phone:386-418-8060
Fax:321-244-8351
Email:[email protected]
Website:https://cyclotherapeutics.com/
Address:6714 NW 16 St Suite B, Gainesville, FL 32653, United States of America
1990
Since
1
Country
1
Top Service Category
4
Sub-Service Categories
API/Biologicals Production
Reagents/excipients manufactured
United States of America
- (12.May.2022) Cyclo Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
- (24.Mar.2022) Cyclo Therapeutics Enters Research and Collaboration Agreement With Wits Commercial Enterprise (Pty) LTD to Explore Potential Applications of Trappsol Cyclo to Expand Pipeline
- (14.Mar.2022) Cyclo Therapeutics Provides Business Update and Reports Full Year 2021 Financial Results
- (08.Feb.2022) Cyclo Therapeutics Selected to Present Overview of Pivotal Phase 3 Study for Lead Candidate, Trappsol Cyclo, at WORLDSymposium 2022
- (03.Feb.2022) Cyclo Therapeutics Announces Formation of Global Steering Committee Comprised of Leading Experts to Advise on the Global Phase 3 Clinical Development Program for Trappsol Cyclo in Niemann-Pick Disease Type C
- (09.Dec.2021) Cyclo Therapeutics Appoints Caroline Hastings, M.D. As Global Principal Investigator for Ongoing TransportNPC Study Evaluating Trappsol Cyclo for the Treatment of Niemann-Pick Disease
- (06.Dec.2021) Cyclo Therapeutics Receives IND Clearance From the U.S. FDA to Advance Its Phase 2 Study of Trappsol Cyclo for the Treatment of Alzheimer's Disease
- (17.Nov.2021) Cyclo Therapeutics Announces Pricing of $11.7 Million Underwritten Public Offering of Common Stock
- (16.Nov.2021) Cyclo Therapeutics Submits Investigational New Drug Application to U.S. FDA to Advance Trappsol Cyclo in Phase 2 Study for Treatment of Alzheimer's Disease
- (16.Nov.2021) Cyclo Therapeutics Announces Proposed Public Offering of Common Stock
- (15.Nov.2021) Cyclo Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results
- (19.Oct.2021) Cyclo Therapeutics Recognizes Niemann-Pick Disease Awareness Month Highlighting Need for Broader Awareness and Support for Research to Find a Treatment
- (27.Sep.2021) Cyclo Therapeutics Appoints Lise Lund Kjems, MD, PhD as Chief Medical Officer
- (17.Aug.2021) Cyclo Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results
- (30.Jul.2021) Cyclo Therapeutics Announces New Positive Safety and Efficacy Data from Ongoing Phase 1 Open-Label Extension Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1
- (27.Jul.2021) Cyclo Therapeutics Commences Commercial-Scale Manufacturing for Trappsol Cyclo